Scarica l'app Stockscreener
0.313
7.67%
-0.026
Dopo l'orario di chiusura:
.33
0.017
+5.43%
Precedente Chiudi:
$0.339
Aprire:
$0.3372
Volume 24 ore:
889.14K
Relative Volume:
0.15
Capitalizzazione di mercato:
$5.34M
Reddito:
$743.00K
Utile/perdita netta:
$-7.63M
Rapporto P/E:
-0.1043
EPS:
-3
Flusso di cassa netto:
-
1 W Prestazione:
-10.78%
1M Prestazione:
-24.76%
6M Prestazione:
-71.02%
1 anno Prestazione:
-79.54%
Intervallo 1D:
$0.313
$0.3372
Intervallo di 1 settimana:
$0.313
$0.3948
Portata 52W:
$0.28
$2.33
Can-Fite Biopharma Ltd ADR Stock (CANF) Company Profile
Nome
Can-Fite Biopharma Ltd ADR
Settore
Industria
Telefono
972 3 924 1114
Indirizzo
10 Bareket Street, Kiryat Matalon PO Box 7537, Petah-Tikva
Confronta CANF con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CANF
Can-Fite Biopharma Ltd ADR
|
0.313 | 5.79M | 743.00K | -7.63M | 0 | -3.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Can-Fite Biopharma Ltd ADR Stock (CANF) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2017-08-11 | Iniziato | Maxim Group | Buy |
| 2016-10-19 | Ripresa | ROTH Capital | Buy |
| 2016-08-29 | Ripresa | Rodman & Renshaw | Buy |
| 2015-11-30 | Reiterato | H.C. Wainwright | Buy |
| 2015-03-31 | Reiterato | H.C. Wainwright | Buy |
| 2015-03-30 | Downgrade | ROTH Capital | Buy → Neutral |
| 2014-12-29 | Reiterato | ROTH Capital | Buy |
| 2014-11-18 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Can-Fite Biopharma Ltd ADR Borsa (CANF) Ultime notizie
Can Can Fite Biopharma Ltd Sponsored ADR stock survive global slowdown2025 Price Momentum & AI Based Trade Execution Alerts - Newser
Will Can Fite Biopharma Ltd Sponsored ADR stock see insider accumulation2025 Fundamental Recap & Daily Technical Forecast Reports - Newser
Can Can Fite Biopharma Ltd Sponsored ADR stock sustain breakout momentum2025 Investor Takeaways & Expert Approved Momentum Ideas - Newser
Can Can Fite Biopharma Ltd Sponsored ADR stock test all time highsMarket Performance Report & Free Expert Approved Momentum Trade Ideas - Newser
How big funds are accumulating Can Fite Biopharma Ltd Sponsored ADR stockDividend Hike & AI Enhanced Trade Execution Alerts - Newser
Is Can Fite Biopharma Ltd Sponsored ADR stock positioned for secular growth2025 Key Lessons & Growth Focused Entry Reports - Newser
Can Can Fite Biopharma Ltd Sponsored ADR stock deliver double digit returnsJuly 2025 Short Interest & Fast Moving Stock Watchlists - Newser
An analyst sees good growth prospects for Can-Fite Biopharma Ltd ADR (CANF) - Setenews
Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference - Sahm
12 Health Care Stocks Moving In Monday's After-Market Session - Sahm
You might want to take a look at Pasithea Therapeutics Corp (KTTA) now - Setenews
Can-Fite’s CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil - Sahm
Will Can Fite Biopharma Ltd Sponsored ADR stock beat revenue estimatesQuarterly Performance Summary & Scalable Portfolio Growth Ideas - newser.com
Why Can Fite Biopharma Ltd Sponsored ADR stock is a strong analyst pickJuly 2025 Intraday Action & Capital Efficient Trading Techniques - newser.com
Can Can Fite Biopharma Ltd Sponsored ADR stock expand revenue streams - newser.com
Take off with Santech Holdings Ltd. ADR (STEC): Get ready for trading - Setenews
How does Can-Fite Biopharma Ltd ADR (CANF) change from a tortoise to a hare? - Setenews
Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson - Sahm
Can-Fite Biopharma Ltd ADR Azioni (CANF) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.44%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):